This week, one of the key players in the COVID-19 vaccine race took a leap forward.On Tuesday, Inovio Pharmaceuticals (INO) announced that Thermo Fisher Scientific had signed a letter of intent to manufacture its DNA COVID-19 vaccine candidate, INO-4800. Thermo Fisher will be added to a list of partners that includes Richter-Helm Biologics and Ology Bioscience. This global manufacturing consortium will support the commercial production of 100 million doses of INO-4800 in 2021, should the candidate ultimately receive FDA approval.H.C. Wainwright’s Raghuram Selvaraju points out that Thermo Fisher plans to manufacture INO-4800 as well as perform the fill and finish …read more
Source:: Yahoo Finance
